We are live on ! Find out more
PVMCV

Polaris Venture Management Co V Portfolio holdings

AUM $14.1M
1-Year Est. Return 121.41%
This Fund
S&P 500
This Quarter Est. Return
+0.97%
1 Year Est. Return
+121.41%
3 Year Est. Return
+281.18%
5 Year Est. Return
+1,023.01%
10 Year Est. Return
–
AUM
$224M
AUM Growth
+$396K
Cap. Flow
+$52.8M
Cap. Flow %
23.55%
Top 10 Hldgs %
100%
Holding
9
New
2
Increased
–
Reduced
3
Closed
–

Top Buys

Rank Stock Value
1
ATYR
aTyr Pharma
ATYR
+$40.5M
2
PULM icon
Pulmatrix
PULM
+$34.9M

Top Sells

Rank Stock Value
1
OCUL icon
Ocular Therapeutix
OCUL
+$19.8M
2
TTOO
T2 Biosystems, Inc
TTOO
+$1.82M
3
GNCA
Genocea Biosciences, Inc.
GNCA
+$1.01M

Sector Composition

Rank Sector Weight
1 Healthcare 78.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TTOO
1
DELISTED
T2 Biosystems, Inc
TTOO
$36.8M 16.43%
454
-21
-4% -$1.82M
PULM icon
2
Pulmatrix
PULM
$6.21M
$34.6M 15.45%
+18,040
New +$34.9M
ATYR
3
aTyr Pharma
ATYR
$47.1M
$33.9M 15.1%
+130,571
New +$40.5M
GNCA
4
DELISTED
Genocea Biosciences, Inc.
GNCA
$27M 12.05%
246,076
-10,828
-4% -$1.01M
OCUL icon
5
Ocular Therapeutix
OCUL
$1.85B
$25.9M 11.54%
1,230,009
-800,000
-39% -$19.8M
TRVN
6
DELISTED
Trevena, Inc.
TRVN
$23.6M 10.52%
6,031
– –
FATE icon
7
Fate Therapeutics
FATE
$293M
$16M 7.14%
2,473,186
– –
DARE icon
8
Dare Bioscience
DARE
$18.6M
$15.1M 6.74%
27,396
– –
BIND
9
DELISTED
BIND THERAPEUTICS INC
BIND
$11.3M 5.03%
2,018,253
– –

Similar funds

IFC
Intact Financial Corporation Toronto, Ontario, Canada $14M AUM
AG
Ashmore Group London, United Kingdom $16.3M AUM 57.83% 1-Year Est. Return
RCM
Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return
IR
Invictus RG Hamilton, Bermuda $8.9M AUM 56.32% 1-Year Est. Return
CCM
Copernicus Capital Management San Francisco, California $8.26M AUM 37.91% 1-Year Est. Return
EIP
Edgbaston Investment Partners $20.3M AUM 35.98% 1-Year Est. Return
AAM
Areion Asset Management Hong Kong $7.82M AUM 16% 1-Year Est. Return
OEP
Ocean Endowment Partners Chicago, Illinois $20.6M AUM 27.63% 1-Year Est. Return

Polaris Venture Management Co V's Q2 2015 Portfolio in Review

As of Q2 2015, Polaris Venture Management Co V held 9 positions worth $224M, up 0.18% from $224M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Polaris Venture Management Co V deployed $52.8M of net new capital in Q2 2015, opening 2 new positions. Its largest new stake was aTyr Pharma: 130,571 shares worth $33.9M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 79% a quarter earlier.

On the sell side, the largest reduction was Ocular Therapeutix, an estimated $19.8M trimmed.

  • Polaris Venture Management Co V's largest Q2 2015 buy was aTyr Pharma: 130,571 shares worth $33.9M.
  • Polaris Venture Management Co V's biggest Q2 2015 reduction was Ocular Therapeutix, cutting an estimated $19.8M.
  • Polaris Venture Management Co V's ten largest holdings make up 100% of its $224M portfolio in Q2 2015.
  • Polaris Venture Management Co V opened 2 new positions and closed 0 in Q2 2015.
  • Polaris Venture Management Co V's portfolio value rose 0.18% quarter-over-quarter to $224M.

Based on Polaris Venture Management Co V's 13F filing for Q2 2015, filed 11 Aug 2015.